IDH3A and neoplasm: Specific driver mutations in isocitrate dehydrogenase (IDH) have been identified in a variety of neoplasms, including cholangiocarcinoma; acute myeloid leukemia; gliomas; thyroid, breast, and prostate carcinomas; and melanoma [14, 18, 25, 27, 31, 37, 42, 43, 46, 47, 49].